March 25, 2024
New PeerLINC Knowledge Hub will Leverage Local Expertise and Experience to Accelerate New, More Effective TB Cures Around the World
Hub will focus on supporting global use of new treatments that effectively treated drug-resistant TB in 98% of Filipino participants
March 25, 2024
Australian Government Grants TB Alliance an Award to Help Bolster Clinical Research and Improve Access to New Treatments for Drug-Resistant TB
AUD 17 Million Grant over 5 Years Will Fund Next-Generation TB Cures
March 24, 2024
Commitment, Innovation and Action are Needed to End TB — On World TB Day, We Reaffirm our Dedication to all Impacted by Tuberculosis
January 31, 2024
Funding for TB and Neglected Diseases Backslides
Statement from TB Alliance on the alarming trend of reduced funding for PDPs
November 16, 2023
TB Alliance Launches Five-Country Phase 2 Clinical Trial Evaluating Next-Generation TB Drug
November 15, 2023
High Cure Rate with Drug-Resistant TB Regimen: Results of Operational Research in Central and Southeast Asia
November 13, 2023
TB Alliance Applauds Macleods’ Launch of a Key Component of WHO-Recommended Drug-Resistant TB Treatment Regimen
Macleods becomes second pharmaceutical manufacturer to bring pretomanid supply to market and first since the World Health Organization issued updated DR-TB treatment guidelines
November 9, 2023
New Drug-Resistant TB Treatments Reach Patients in Pakistan as Association for Social Development Accelerates Pilot Implementation
Preliminary results show increased cure rates for hard-to-treat TB infections; leads to update in Pakistan’s treatment guidelines
November 7, 2023
New WHO Global TB Report Shows Recovery in Effort to Combat TB, But Stronger Investments are Needed to Help Reach UN Goals
Statement from Mel Spigelman, M.D., President and Chief Executive Officer, TB Alliance
September 29, 2023